Lenzing's 99% Take-Up Settles the Financing Question; the Earnings Test Is Still Unanswered
Published on 10/21/2026 at 15:01 | Editorial boerse-global.de
Lenzing's shareholders have all but closed the book on its capital raise. The preliminary subscription result published yesterday shows a take-up ratio of 99.0%, with 34,411,626 new shares subscribed under the offer. What that figure does not do is settle the far more consequential question for anyone holding the stock: whether the Austrian fibre maker can turn a repaired balance sheet into durable earnings.
The distinction matters because the two milestones are being reached on different clocks. Subscription is effectively done. Settlement is not. Delivery of the new shares and their admission to trading on the Vienna Stock Exchange are scheduled for 23 October 2026, but that date hinges on the capital increase being entered in the commercial register. Until that filing clears, the timetable is planned rather than guaranteed.
A near-complete book, with a syndicate backstop
The mechanics behind the 99% figure are straightforward. Rights were exercised for all but a sliver of the offer, and the consortium banks will place the small remainder on the market. According to APA, 18,159,291 of the subscribed shares went to the syndicate formed by B&C-Gruppe and Suzano S.A. — a block already counted inside the overall subscription total, not an addition to it.
Board-level participation was also on show. Georg Kasperkovitz and Christian Skilich exercised their subscription rights on 12 October, a detail that documents the two executives' involvement in the offer without carrying any independent read-through for the share price.
The raise itself generated gross proceeds of EUR 301.2 million at an offer price of EUR 8.65 per share. Lenzing intends to deploy the money to shore up its capital structure and to fund its "Grow Nonwovens, Reset Textiles" programme. A strong subscription book answers the demand question. It says nothing about revenue, profit or where the stock goes next.
Should investors sell immediately? Or is it worth buying Lenzing?
The leverage ratio becomes the scorecard
For investors weighing the equity story, the number to watch is net debt relative to EBITDA. Reuters reports that management is targeting a multiple below 2.5x over the medium term — a metric that ties financing directly to earning power and therefore carries more information than the cash inflow on its own.
Two further medium-term ambitions sit alongside it: an EBITDA improvement of EUR 150 million and an EBITDA margin of 20–25%. Both are objectives, not results already banked. A lower leverage multiple can in principle come from either a smaller net debt pile or a larger EBITDA, and in the best case the two reinforce each other.
That interplay is the real test. A stronger capital structure buys breathing room; a higher operating result is what would ultimately justify it. Restating the medium-term targets would carry less weight than visible progress toward hitting them.
Why the market did not cheer the announcement
There is a cautionary note in the history here. Reuters reports that the capital increase, announced at the start of October, was what triggered the share price decline at the time. The financing was not received purely as an opportunity, and the completion of the placement does not by itself invite a re-rating.
The bear case is substantive rather than reflexive. A finished raise does not automatically lift profitability. If operating progress lags the stated ambitions, the new equity will have strengthened the starting position without moving the leverage ratio close enough to target — and valuation would then have to separate financial relief from genuine turnaround success. Treating the capital inflow as a down payment on higher profits is precisely the risk; until operating trends support that expectation, the bullish case stays conditional.
Two dates, two different questions
What comes next splits cleanly in two. The near-term catalyst is administrative: settlement, delivery and the start of trading under the existing ISIN, all contingent on the commercial register entry. The larger question is economic — what the company actually does with the money.
The upside scenario has Lenzing using the proceeds to execute the announced strategy, with a rising EBITDA easing the leverage ratio from the earnings side as well. Getting closer to the margin target would be the tell that improvement is not merely an artefact of fresh capital. Progress on earnings and financial stabilisation would need to arrive together to make the case convincing.
For now the two threads remain separate. The subscription result proves demand for the offer; it does not prove the turnaround. Lenzing's next real examination is the execution of its strategy — not a placement that is, for practical purposes, already in the books.
Ad
Lenzing Stock: New Analysis - 21 October
Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
